https://vaccinescongress.com/cpd-accreditation 0.9 https://vaccinescongress.com/ 1.0 https://vaccinescongress.com/program/scientific-sessions 0.9 https://vaccinescongress.com/program/scientific-program 0.9 https://vaccinescongress.com/information/welcome-message 0.9 https://vaccinescongress.com/information/venue 0.9 https://vaccinescongress.com/information/accommodation 0.9 https://vaccinescongress.com/information/guidelines 0.9 https://vaccinescongress.com/information/faq 0.9 https://vaccinescongress.com/information/important-dates 0.9 https://vaccinescongress.com/information/conference-brochure 0.9 https://vaccinescongress.com/about/past-events 0.9 https://vaccinescongress.com/about/about-organizer 0.9 https://vaccinescongress.com/about/testimonials-reviews 0.9 https://vaccinescongress.com/contact 0.9 https://vaccinescongress.com/submit-abstract 0.9 https://vaccinescongress.com/register 0.9 https://vaccinescongress.com/general-information 0.9 https://vaccinescongress.com/privacy-policy 0.9 https://vaccinescongress.com/terms-and-conditions 0.9 https://vaccinescongress.com/video-gallery 0.9 https://vaccinescongress.com/gallery 0.9 https://vaccinescongress.com/scientific-committee/2026 0.8 https://vaccinescongress.com/scientific-committee/2025 0.8 https://vaccinescongress.com/scientific-committee/2024 0.8 https://vaccinescongress.com/scientific-committee/2023 0.8 https://vaccinescongress.com/scientific-committee/2022 0.8 https://vaccinescongress.com/scientific-committee/2021 0.8 https://vaccinescongress.com/speakers/2026 2026-05-16 0.8 https://vaccinescongress.com/speakers/2025 0.8 https://vaccinescongress.com/speakers/2024 0.8 https://vaccinescongress.com/speakers/2023 0.8 https://vaccinescongress.com/speakers/2022 0.8 https://vaccinescongress.com/speakers/2021 0.8 https://vaccinescongress.com/speaker/duccio-medini 0.8 https://vaccinescongress.com/speaker/sergey-v-suchkov 0.8 https://vaccinescongress.com/speaker/zhujun-ao 0.8 https://vaccinescongress.com/speaker/huanhuan-li 0.8 https://vaccinescongress.com/speaker/lei-chen 0.8 https://vaccinescongress.com/speaker/ashish-kumar-maurya 0.8 https://vaccinescongress.com/speaker/sajal-dey 0.8 https://vaccinescongress.com/speaker/ayman-h-m-el-deeb 0.8 https://vaccinescongress.com/speaker/aysel-sadayli 0.8 https://vaccinescongress.com/speaker/millicent-ochieng 0.8 https://vaccinescongress.com/speaker/shenglan-tang 0.8 https://vaccinescongress.com/speaker/katia-alves 0.8 https://vaccinescongress.com/speaker/zwile-zungu 0.8 https://vaccinescongress.com/speaker/prince-kyere-dwaah 0.8 https://vaccinescongress.com/speaker/amira-nabil-abdel-hamid-ahmed 0.8 https://vaccinescongress.com/speaker/jesse-kuiper 0.8 https://vaccinescongress.com/speaker/ying-wan 0.8 https://vaccinescongress.com/speaker/eric-kemp 0.8 https://vaccinescongress.com/speaker/ria-t-caringal 0.8 https://vaccinescongress.com/speaker/ahmed-abdulazeez 0.8 https://vaccinescongress.com/speaker/yen-hung-chow 0.8 https://vaccinescongress.com/speaker/vianey-jetzabel-del-mercado-gonzalez 0.8 https://vaccinescongress.com/speaker/junmei-zhang 0.8 https://vaccinescongress.com/speaker/shuqi-xiao 0.8 https://vaccinescongress.com/speaker/k-r-aneja 0.8 https://vaccinescongress.com/speaker/manish-tripathi 0.8 https://vaccinescongress.com/speaker/rachana 0.8 https://vaccinescongress.com/speaker/adhaar-kohli 0.8 https://vaccinescongress.com/speaker/aini-syahida-mat-yassim 0.8 https://vaccinescongress.com/speaker/aghapy-yermans-yakoup 0.8 https://vaccinescongress.com/speaker/manuel-antonio-sierra-santos 0.8 https://vaccinescongress.com/speaker/negar-seyed 0.8 https://vaccinescongress.com/speaker/leila-salimi 0.8 https://vaccinescongress.com/speaker/jeniffer-n-adungosi 0.8 https://vaccinescongress.com/speaker/charles-ugochukwu-ibeneme 0.8 https://vaccinescongress.com/speaker/whegang-youdom-solange 0.8 https://vaccinescongress.com/speaker/leontine-kouemou-sinda 0.8 https://vaccinescongress.com/speaker/attahir-abubakar 0.8 https://vaccinescongress.com/speaker/meseret-girma-abate 0.8 https://vaccinescongress.com/speaker/ping-xie 0.8 https://vaccinescongress.com/speaker/agostino-riva 0.8 https://vaccinescongress.com/speaker/david-craig-wright 0.8 https://vaccinescongress.com/speaker/carly-contri 0.8 https://vaccinescongress.com/speaker/chitra-upadhyay 0.8 https://vaccinescongress.com/speaker/jocelyn-jakubik 0.8 https://vaccinescongress.com/speaker/lindsay-parish 0.8 https://vaccinescongress.com/speaker/megha-mummalaneni 0.8 https://vaccinescongress.com/speaker/erez-shmueli 0.8 https://vaccinescongress.com/speaker/patrycja-dolibog 0.8 https://vaccinescongress.com/speaker/yi-liu 0.8 https://vaccinescongress.com/speaker/rajib-deb 0.8 https://vaccinescongress.com/speaker/madhu-khanna 0.8 https://vaccinescongress.com/speaker/dalinda-eusebio 0.8 https://vaccinescongress.com/speaker/asmamaw-bihonegn 0.8 https://vaccinescongress.com/speaker/samson-gebremedhin-gebreselassie 0.8 https://vaccinescongress.com/speaker/brandon-lucke-wold 0.8 https://vaccinescongress.com/speaker/regina-au 0.8 https://vaccinescongress.com/speaker/devarshi-brahmbhatt 0.8 https://vaccinescongress.com/speaker/sushmita-koley 0.8 https://vaccinescongress.com/speaker/olivia-viscuso 0.8 https://vaccinescongress.com/speaker/sonal-gidwani 0.8 https://vaccinescongress.com/speaker/indira-acharya 0.8 https://vaccinescongress.com/speaker/joe-smyser 0.8 https://vaccinescongress.com/speaker/kristen-lee-moriarty 0.8 https://vaccinescongress.com/speaker/bethan-charlotte-hussey 0.8 https://vaccinescongress.com/speaker/paul-van-buynder 0.8 https://vaccinescongress.com/speaker/daniel-becker 0.8 https://vaccinescongress.com/speaker/joana-kira-besecke 0.8 https://vaccinescongress.com/speaker/levast-benoit 0.8 https://vaccinescongress.com/speaker/nsana-sjelin-nardiouf 0.8 https://vaccinescongress.com/speaker/massimo-florio 0.8 https://vaccinescongress.com/speaker/diego-tomassone 0.8 https://vaccinescongress.com/speaker/ismail 0.8 https://vaccinescongress.com/speaker/lev-ramirez 0.8 https://vaccinescongress.com/speaker/nzolameso-makaya-jennifer 0.8 https://vaccinescongress.com/speaker/maduike-chiehiura-onwubiko-ezeibe 0.8 https://vaccinescongress.com/speaker/vincenzo-alfano 0.8 https://vaccinescongress.com/speaker/sudhakar-bangera 0.8 https://vaccinescongress.com/speaker/rosane-cuber-guimaraes 0.8 https://vaccinescongress.com/speaker/mayra-ramos-suzarte 0.8 https://vaccinescongress.com/speaker/deborah-hilton 0.8 https://vaccinescongress.com/speaker/vasiliki-georgakopoulou 0.8 https://vaccinescongress.com/speaker/alex-zhu 0.8 https://vaccinescongress.com/speaker/christine-bricault 0.8 https://vaccinescongress.com/speaker/angelo-tunin-chica-pergo 0.8 https://vaccinescongress.com/speaker/sissy-therese-sonnleitner 0.8 https://vaccinescongress.com/speaker/yusuf-ziya-sener 0.8 https://vaccinescongress.com/speaker/amarjeet-gambhir 0.8 https://vaccinescongress.com/speaker/hemanta-kumar-kar 0.8 https://vaccinescongress.com/speaker/yusuke-oji 0.8 https://vaccinescongress.com/speaker/huixing-lin 0.8 https://vaccinescongress.com/speaker/satyabrata-dandapat 0.8 https://vaccinescongress.com/speaker/jamil-m-a-s-obaid 0.8 https://vaccinescongress.com/speaker/seyedeh-sajedeh-mousavi 0.8 https://vaccinescongress.com/speaker/mohammad-zoladl 0.8 https://vaccinescongress.com/speaker/sawsan-abuhammad 0.8 https://vaccinescongress.com/speaker/mina-ziarati 0.8 https://vaccinescongress.com/speaker/joseph-anejo-okopi 0.8 https://vaccinescongress.com/speaker/laleh-yazdanpanah-goharrizi 0.8 https://vaccinescongress.com/speaker/solange-whegang-youdom 0.8 https://vaccinescongress.com/speaker/emmanuel-ifeanyi-obeagu 0.8 https://vaccinescongress.com/speaker/hao-song 0.8 https://vaccinescongress.com/speaker/patricia-canteri-de-souza 0.8 https://vaccinescongress.com/speaker/heather-mathie 0.8 https://vaccinescongress.com/speaker/irina-zyrianova 0.8 https://vaccinescongress.com/speaker/afshona-anoyatbekova 0.8 https://vaccinescongress.com/speaker/khursheed-nadeem-anwer 0.8 https://vaccinescongress.com/speaker/alessia-quatela 0.8 https://vaccinescongress.com/speaker/huang-wei-ling 0.8 https://vaccinescongress.com/speaker/luiza-guilherme 0.8 https://vaccinescongress.com/speaker/alibek-adil 0.8 https://vaccinescongress.com/speaker/idania-marrero 0.8 https://vaccinescongress.com/speaker/gaurav-joshi 0.8 https://vaccinescongress.com/speaker/domenico-merante 0.8 https://vaccinescongress.com/speaker/azadeh-zahmatkesh 0.8 https://vaccinescongress.com/speaker/julia-bespyatykh 0.8 https://vaccinescongress.com/speaker/lamiae-grimaldi-bensouda 0.8 https://vaccinescongress.com/speaker/mohamed-m-jahromi 0.8 https://vaccinescongress.com/speaker/maryam-touhidinia 0.8 https://vaccinescongress.com/speaker/ghadir-fakhri-al-jayyousi 0.8 https://vaccinescongress.com/speaker/sanjeeb-kumar-mishra 0.8 https://vaccinescongress.com/speaker/damini-singh 0.8 https://vaccinescongress.com/speaker/mohammad-jalil-zorriehzahra 0.8 https://vaccinescongress.com/speaker/k-m-yacob 0.8 https://vaccinescongress.com/speaker/mahya-sadat-lajevardi 0.8 https://vaccinescongress.com/speaker/muhammad-naveed-anwar 0.8 https://vaccinescongress.com/speaker/m-jalil-zorriehzahra 0.8 https://vaccinescongress.com/speaker/yacob-mathai 0.8 https://vaccinescongress.com/speaker/ismail-hossain 0.8 https://vaccinescongress.com/speaker/jennifer-elaine-gerber 0.8 https://vaccinescongress.com/program/scientific-program/2026 2026-05-16 0.8 https://vaccinescongress.com/program/scientific-program/2025 0.8 https://vaccinescongress.com/program/scientific-program/2024 0.8 https://vaccinescongress.com/program/scientific-program/2023 0.8 https://vaccinescongress.com/program/scientific-program/2022 0.8 https://vaccinescongress.com/program/scientific-program/2021 0.8 https://vaccinescongress.com/program/scientific-program/2026/a-universal-ai-design-framework-and-brokerage-platform-for-democratised-manufacturing-of-mrna-therapeutics 0.8 https://vaccinescongress.com/program/scientific-program/2026/personalized-and-precision-medicine-ppm-via-biodesign-driven-translational-applications-and-upgraded-business-modeling-to-secure-the-human-biosafety-the-next-step-vaccinomics-of-the-future 0.8 https://vaccinescongress.com/program/scientific-program/2026/development-of-vsv-vector-based-vaccine-against-h5n1-avian-influenza-by-targeting-both-h5n1-hemagglutinin-and-matrix-protein-2 0.8 https://vaccinescongress.com/program/scientific-program/2026/a-novel-responsive-microneedle-platform-for-reliable-drug-and-vaccine-delivery 0.8 https://vaccinescongress.com/program/scientific-program/2026/the-promise-of-nanotechnology-in-personalized-precision-medicine-nano-driven-precision-vaccinomics-of-the-future 0.8 https://vaccinescongress.com/program/scientific-program/2026/comparative-efficacy-of-different-h9n2-avian-influenza-virus-inactivated-vaccines-using-some-commercially-available-adjuvants-for-superior-control-in-broilers 0.8 https://vaccinescongress.com/program/scientific-program/2026/structure-based-design-and-development-of-next-generation-respiratory-syncytial-virus-rsv-vaccine 0.8 https://vaccinescongress.com/program/scientific-program/2026/unmasking-urban-immunization-inequities-a-cross-sectional-lqas-analysis-of-zero-dose-drivers-in-slum-and-non-slum-settings-of-uttar-pradesh-india 0.8 https://vaccinescongress.com/program/scientific-program/2026/advancing-vaccine-availability-and-equity-in-low-resource-settings-evidence-from-awendo-sub-county-kenya 0.8 https://vaccinescongress.com/program/scientific-program/2026/responding-to-mpox-in-africa-vaccine-strategy-during-sustained-human-transmission 0.8 https://vaccinescongress.com/program/scientific-program/2026/from-local-pilots-to-national-policy-key-issues-and-challenges-in-implementing-nationwide-hpv-vaccination-in-china 0.8 https://vaccinescongress.com/program/scientific-program/2026/understanding-sars-cov-2-vaccine-hesitancy-among-pregnant-women-in-soweto-south-africa-a-qualitative-study 0.8 https://vaccinescongress.com/program/scientific-program/2026/recombinant-bcg-vaccine-as-a-potent-anti-tuberculosis-vaccine-candidate 0.8 https://vaccinescongress.com/program/scientific-program/2026/vaccines-for-diabetes-and-associated-infections-in-diabetic-patients 0.8 https://vaccinescongress.com/program/scientific-program/2026/engineered-extracellular-vesicles-vaccines-with-conserved-peptides-induce-robust-immune-defense-against-influenza-virus 0.8 https://vaccinescongress.com/program/scientific-program/2026/emerging-nanovaccine-strategies-for-enhanced-immune-targeting-and-vaccine-performance 0.8 https://vaccinescongress.com/program/scientific-program/2026/reaching-zero-dose-children-through-adaptive-immunization-strategies-in-security-compromised-areas-of-zamfara-state-nigeria 0.8 https://vaccinescongress.com/program/scientific-program/2026/community-knowledge-risk-perception-and-health-seeking-behaviour-toward-rabies-in-ghana-one-health-implications 0.8 https://vaccinescongress.com/program/scientific-program/2026/safety-and-immunogenicity-of-different-antigen-and-adjuvant-booster-dose-levels-of-protein-based-novavax-covid-19-vaccines-in-adults-50-years-previously-vaccinated-with-mrna-covid-19-vaccines 0.8 https://vaccinescongress.com/program/scientific-program/2025/nanoscopic-subatvax-adjuvanted-vaccines-against-influenza-a-types-h3n2-h1n1-and-influenza-type-b-for-subcutaneous-administration 0.8 https://vaccinescongress.com/program/scientific-program/2025/a-promising-novel-approach-to-dna-vaccines 0.8 https://vaccinescongress.com/program/scientific-program/2025/establishing-a-platform-method-for-physical-appearance-assessment-of-new-parenteral-pharmaceuticals 0.8 https://vaccinescongress.com/program/scientific-program/2025/overcoming-biophysical-characterization-challenges-of-small-antigens-in-dilute-vaccine-formulations 0.8 https://vaccinescongress.com/program/scientific-program/2025/a-combined-lc-ms-and-immunoassay-approach-to-characterize-preservative-induced-destabilization-of-human-papillomavirus-virus-like-particles-adsorbed-to-an-aluminum-salt-adjuvant 0.8 https://vaccinescongress.com/program/scientific-program/2025/development-of-a-broad-spectrum-vaccine-against-enterovirus-based-on-adenovirus-expression-viral-like-particles 0.8 https://vaccinescongress.com/program/scientific-program/2025/establishment-of-a-high-throughput-fluorescent-antibody-to-membrane-antigen-assay-to-measure-the-humoral-immune-response-against-the-varicella-zoster-virus 0.8 https://vaccinescongress.com/program/scientific-program/2025/commensal-bacteria-drive-b-cell-lymphomagenesis-in-the-setting-of-innate-immunodeficiency 0.8 https://vaccinescongress.com/program/scientific-program/2025/evaluating-the-immunogenic-impact-of-process-impurities-in-mrna-vaccine-production-establishing-integrated-control-strategies-and-specifications 0.8 https://vaccinescongress.com/program/scientific-program/2025/transforming-vaccines-access-through-cost-efficient-last-mile-delivery-models-in-lmics 0.8 https://vaccinescongress.com/program/scientific-program/2025/the-importance-of-post-marketing-surveillance-and-real-world-data-for-a-product-to-be-successful 0.8 https://vaccinescongress.com/program/scientific-program/2025/prophylactic-and-molecular-approaches-for-mitigating-human-influenza-a-viruses-i-evaluating-influenza-vaccine-effectiveness-in-the-older-population-ii-down-regulation-of-influenza-virus-genes-with-novel-sirna-chimeric-ribozyme-constructs 0.8 https://vaccinescongress.com/program/scientific-program/2025/the-role-of-immunity-in-the-pathogenesis-of-sars-cov-2-and-in-the-protection-generated-by-covid-19-in-different-age-groups 0.8 https://vaccinescongress.com/program/scientific-program/2025/in-silico-and-experimental-evaluation-of-the-immunogenic-efficacy-of-a-dna-wt1-vaccine-in-a-murine-model 0.8 https://vaccinescongress.com/program/scientific-program/2025/mapping-virulence-attenuation-sites-in-pedv-genome-implications-for-rational-vaccine-design 0.8 https://vaccinescongress.com/program/scientific-program/2025/immunosuppression-in-covid-19-patients-and-emerging-fungal-infections-vaccines-siagnosis-and-strategies-to-treat-comorbidities 0.8 https://vaccinescongress.com/program/scientific-program/2025/yeast-derived-exosomes-as-a-transformative-platform-for-next-generation-vaccine-development 0.8 https://vaccinescongress.com/program/scientific-program/2025/why-is-the-vaccine-life-threatening-if-people-get-a-fever-after-a-covid-19-vaccination 0.8 https://vaccinescongress.com/program/scientific-program/2025/integrating-next-generation-vaccine-technologies-immunoinformatic-and-public-health-policy-for-rapid-disease-control-insights-from-india 0.8 https://vaccinescongress.com/program/scientific-program/2025/differential-neutralizing-igg-s-and-igg-n-antibody-levels-against-circulating-sars-cov-2-vocs-following-homologous-and-heterologous-boosting-with-bnt162b2-a-22-month-prospective-study 0.8 https://vaccinescongress.com/program/scientific-program/2025/characterization-antibacterial-and-cytotoxic-activities-of-silver-nanoparticles-using-the-whole-biofilm-layer-as-a-macromolecule-in-biosynthesis 0.8 https://vaccinescongress.com/program/scientific-program/2025/mpox-vaccination-in-africa-one-year-on-lessons-and-milestones-from-the-continental-response 0.8 https://vaccinescongress.com/program/scientific-program/2025/post-covid-19-syndrome-is-associated-with-sex-and-severity-of-first-covid-19-episode-in-honduras 0.8 https://vaccinescongress.com/program/scientific-program/2025/new-biomarkers-in-leishmania-major-vaccine-development 0.8 https://vaccinescongress.com/program/scientific-program/2025/exosome-based-vaccine-for-the-therapy-of-cancer 0.8 https://vaccinescongress.com/program/scientific-program/2025/beyond-coverage-estimates-leveraging-analytical-approaches-from-cameroon-s-multiple-indicators-cluster-survey-mics-to-strengthen-future-immunization-planning 0.8 https://vaccinescongress.com/program/scientific-program/2025/assessment-of-vaccine-hesitancy-to-a-covid-19-vaccine-in-cameroonian-adults-and-its-global-implication 0.8 https://vaccinescongress.com/program/scientific-program/2025/optimal-complementary-feeding-practices-and-associated-factors-among-children-6-23-months-old-in-konso-zone-south-ethiopia 0.8 https://vaccinescongress.com/program/scientific-program/2025/exploring-a-novel-interaction-between-the-human-malaria-parasite-plasmodium-vivax-and-reticulocyte-protein 0.8 https://vaccinescongress.com/program/scientific-program/2025/awareness-and-acceptability-of-rotavirus-vaccine-among-mothers-of-under-five-children-in-gusau-and-bungudu-communities-of-zamfara-state-northwestern-nigeria 0.8 https://vaccinescongress.com/program/scientific-program/2024/novel-regulatory-mechanisms-of-innate-immunity-and-inflammation 0.8 https://vaccinescongress.com/program/scientific-program/2024/neutralizing-antibodies-response-to-sars-cov-2-xbb1-5-mrna-vaccine-in-nephrology-patients-on-dialysis-against-different-viral-variants 0.8 https://vaccinescongress.com/program/scientific-program/2024/the-influence-of-physical-factors-on-recombinant-human-serum-albumin 0.8 https://vaccinescongress.com/program/scientific-program/2024/current-investments-and-future-directions-of-biomedical-advanced-research-and-development-authority-s-cbrn-vaccines-portfolio 0.8 https://vaccinescongress.com/program/scientific-program/2024/the-ethiopian-vaccine-supply-chain-and-logistics-system-s-performance-after-the-last-mile-delivery-initiative-phenomenological-study 0.8 https://vaccinescongress.com/program/scientific-program/2024/development-of-a-polyepitope-based-immunogen-for-inducing-cellular-immunity-against-all-dengue-virus-serotypes 0.8 https://vaccinescongress.com/program/scientific-program/2024/development-of-nanobody-armored-dc-vaccine-baizedc-and-its-preliminary-exploration-in-preventing-solid-tumor-recurrence 0.8 https://vaccinescongress.com/program/scientific-program/2024/multiplexed-serology-assays-for-detection-of-igg-antibodies-against-mpox-and-vaccinia-viruses 0.8 https://vaccinescongress.com/program/scientific-program/2024/a-novel-multiplex-serology-assay-to-evaluate-immune-response-to-rsv-sars-cov-2-and-influenza 0.8 https://vaccinescongress.com/program/scientific-program/2024/comprehensive-analysis-of-immunization-program-efficacy-in-bahir-dar-city-a-six-month-retrospective-study 0.8 https://vaccinescongress.com/program/scientific-program/2024/human-challenge-clinical-trial-of-vaccines-for-infectious-diseases-a-necessary-evil 0.8 https://vaccinescongress.com/program/scientific-program/2024/why-antimicrobial-resistance-is-a-global-threat-and-its-impact-on-everyone 0.8 https://vaccinescongress.com/program/scientific-program/2024/targeted-delivery-of-a-minicircle-dna-vaccine-against-covid-19-to-antigen-presenting-cells-using-mannosylated-polyethylenimine-cholesterol-based-nanoparticles 0.8 https://vaccinescongress.com/program/scientific-program/2024/leveraging-power-bi-to-assess-community-immunization-efforts 0.8 https://vaccinescongress.com/program/scientific-program/2024/distinct-mechanisms-regulate-the-exposure-of-broadly-neutralizing-antibody-epitopes-on-hiv-1-particles 0.8 https://vaccinescongress.com/program/scientific-program/2024/using-google-trends-to-gain-insight-into-covid-19-hesitancy-distribution-in-the-united-states 0.8 https://vaccinescongress.com/program/scientific-program/2024/preparation-of-subatvax-adjuvanted-vaccines-against-inactivated-poliovirus-diphtheria-toxoid-tetanus-toxoid-acellular-pertussis-neisseria-meningitidis-streptococcus-pneumoniae-and-haemophilus-influenzae-polysaccharide-conjugates-for-subcutaneous-administration 0.8 https://vaccinescongress.com/program/scientific-program/2024/immunogenicity-and-efficacy-of-a-subcutaneously-administered-adjuvanted-vaccine-containing-modified-s1-spike-protein-of-sars-cov-2-variant-c-1-2 0.8 https://vaccinescongress.com/program/scientific-program/2024/preparation-characterization-and-stability-of-subatvax-adjuvanted-commercial-veterinary-vaccines-using-six-commercial-vaccines-including-rabies-leptospirosis-and-an-encephalomyelitis-combination-vaccine-for-subcutaneous-administration 0.8 https://vaccinescongress.com/program/scientific-program/2024/higher-sensitivity-monitoring-of-reactions-to-vaccination-using-smartwatches 0.8 https://vaccinescongress.com/program/scientific-program/2024/development-of-a-virus-like-particle-against-indian-isolate-of-porcine-circovirus-2d 0.8 https://vaccinescongress.com/program/scientific-program/2023/vaccines-and-monoclonal-antibodies-in-the-prolonged-treatment-of-non-small-cell-lung-cancer-20-years-of-follow-up 0.8 https://vaccinescongress.com/program/scientific-program/2023/observational-study-post-emergency-use-authorization-of-itolizumab-in-the-treatment-of-covid-19 0.8 https://vaccinescongress.com/program/scientific-program/2023/a-cross-sectional-study-to-evaluate-people-knowledge-attitude-and-practice-towards-using-disinfectants-and-sanitizers-during-covid-19-pandemic-in-bangladesh 0.8 https://vaccinescongress.com/program/scientific-program/2023/nirmatrelvir-ritonavir-counseling-and-acceptance-in-pregnancy 0.8 https://vaccinescongress.com/program/scientific-program/2023/mapping-of-long-term-public-and-private-investments-in-the-development-of-covid19-vaccines 0.8 https://vaccinescongress.com/program/scientific-program/2023/vaccination-of-older-persons-towards-a-population-approach-lessons-from-sars-cov-2-in-australia 0.8 https://vaccinescongress.com/program/scientific-program/2023/reactive-arthritis-following-mpox-monkey-pox-vaccination 0.8 https://vaccinescongress.com/program/scientific-program/2023/management-of-arterial-hypertension-and-diabetes-in-elderly-people-as-well-as-covid-19-prevention 0.8 https://vaccinescongress.com/program/scientific-program/2023/association-between-covid-19-vaccination-and-menstrual-disturbances-a-retrospective-cohort-analysis 0.8 https://vaccinescongress.com/program/scientific-program/2023/assessing-political-sorting-in-response-to-covid-19-vaccine-mandates-a-preliminary-analysis 0.8 https://vaccinescongress.com/program/scientific-program/2023/lessons-learned-for-the-future-of-social-listening-to-address-vaccine-misinformation 0.8 https://vaccinescongress.com/program/scientific-program/2023/fungal-vaccines-are-they-important-to-have 0.8 https://vaccinescongress.com/program/scientific-program/2023/purification-process-development-of-covid-antigens-to-identify-sera-needed-for-plasma-therapy 0.8 https://vaccinescongress.com/program/scientific-program/2023/developing-a-network-supporting-sars-cov-2-assays-vaccine-clinical-trials-through-the-cepi-centralized-laboratory-network 0.8 https://vaccinescongress.com/program/scientific-program/2023/nlr-as-a-diagnostic-and-prognostic-marker-for-neonatal-sepsis-a-systemic-review 0.8 https://vaccinescongress.com/program/scientific-program/2023/impact-of-the-long-acting-insecticide-treated-mosquitonet-in-the-strategy-to-combat-malaria-vectors-in-the-republic-of-congo-from-2012-2017 0.8 https://vaccinescongress.com/program/scientific-program/2023/novel-dosimeters-for-process-control-of-next-generation-production-of-vaccines-and-immune-therapeutics 0.8 https://vaccinescongress.com/program/scientific-program/2023/3d-vaxlock-technology-stabilizes-the-prefusion-conformation-of-the-rsv-f-protein-resulting-in-a-highly-potent-and-stable-subunit-vaccine-candidate 0.8 https://vaccinescongress.com/program/scientific-program/2023/3d-vaxlock-technology-stabilizes-the-prefusion-conformation-of-the-rsv-f-protein-resulting-in-a-highly-potent-and-stable-subunit-vaccine-candidate 0.8 https://vaccinescongress.com/program/scientific-program/2023/will-host-genetics-influence-the-response-and-risk-of-adverse-reactions-to-sars-cov-2-vaccines-historical-precedents 0.8 https://vaccinescongress.com/program/scientific-program/2023/missed-opportunities-for-vaccination-among-children-aged-0-to-23-months-in-cameroon 0.8 https://vaccinescongress.com/program/scientific-program/2023/lessons-learned-from-the-covid-19-vaccine-and-what-is-needed-when-developing-a-vaccine-for-a-successful-rollout 0.8 https://vaccinescongress.com/program/scientific-program/2023/why-low-energy-electron-irradiation-might-be-a-potential-game-changer-for-vaccine-development-manufacturing-and-pandemics-prevention 0.8 https://vaccinescongress.com/program/scientific-program/2023/medicinal-synthetic-aluminum-magnesium-silicate-al4-sio4-3-3mg2sio4-2al2-mg3-sio4-3-effective-for-viral-diseases-tumors-antimicrobial-resistant-infections 0.8 https://vaccinescongress.com/program/scientific-program/2023/a-dna-based-vaccine-technology-independent-of-a-virus-or-device 0.8 https://vaccinescongress.com/program/scientific-program/2023/system-serology-approach-on-covid-19-patients-sera-reveal-specific-immune-pattern-in-the-heterogeneous-population-the-covidaura-study 0.8 https://vaccinescongress.com/program/scientific-program/2022/the-need-for-separate-regulations-for-prophylactic-vaccines 0.8 https://vaccinescongress.com/program/scientific-program/2022/analytical-transfer-of-covid-19-recombinant-vaccine-between-fiocruz-and-astrazeneca 0.8 https://vaccinescongress.com/program/scientific-program/2022/development-and-validation-of-a-specific-tool-to-assess-vaccination-hesitation-during-the-covid-19-pandemic 0.8 https://vaccinescongress.com/program/scientific-program/2022/mip-vaccine-and-leprosy-our-20-year-research-journey-from-1986-to-2005 0.8 https://vaccinescongress.com/program/scientific-program/2022/factors-predicting-poor-outcomes-of-patients-treated-with-tocilizumab-for-covid-19-pneumonia-a-retrospective-study 0.8 https://vaccinescongress.com/program/scientific-program/2022/onodera-s-prognostic-nutritional-index-comparison-of-its-role-in-severity-and-outcomes-of-covid-19-patients-among-the-periods-of-alpha-delta-and-omicron-variant-predominance 0.8 https://vaccinescongress.com/program/scientific-program/2022/the-potential-application-of-recombinant-swinepox-virus-expressing-protective-antigens-of-asfv 0.8 https://vaccinescongress.com/program/scientific-program/2022/missed-opportunities-for-vaccination-and-associated-factors-among-children-aged-12-23-months-in-cameroon 0.8 https://vaccinescongress.com/program/scientific-program/2022/covid-19-mucormycosis 0.8 https://vaccinescongress.com/program/scientific-program/2022/strategic-efforts-towards-development-of-a-cell-culture-attenuated-duck-plague-vaccine-using-an-indian-virulent-field-isolate 0.8 https://vaccinescongress.com/program/scientific-program/2022/vaccination-in-cardiovascular-diseases 0.8 https://vaccinescongress.com/program/scientific-program/2022/global-covid-19-vaccine-policies-a-literature-review 0.8 https://vaccinescongress.com/program/scientific-program/2022/robust-antibody-mediated-protection-against-sars-cov-2-induced-by-nvx-cov2373-subunit-vaccine-adjuvanted-with-matrix-m 0.8 https://vaccinescongress.com/program/scientific-program/2022/comparison-between-virulent-genes-based-and-serotype-based-vaccine-for-uropathogenic-escherichia-coli 0.8 https://vaccinescongress.com/program/scientific-program/2022/your-vaccine-attitude-determines-your-altitude-what-are-the-determinants-of-attitude-toward-vaccination 0.8 https://vaccinescongress.com/program/scientific-program/2022/therapeutic-repositioning-of-the-monoclonal-antibodies-itolizumab-and-nimotuzumab-in-covid-19 0.8 https://vaccinescongress.com/program/scientific-program/2022/characterization-of-prefusion-f-specific-antibodies-elicited-by-natural-infection-with-human-metapneumovirus-from-two-older-adults 0.8 https://vaccinescongress.com/program/scientific-program/2022/immune-responses-to-inactivated-vaccine-against-covid-19-covivac-in-adults-individuals 0.8 https://vaccinescongress.com/program/scientific-program/2022/new-developments-in-the-field-of-aquatics-vaccination-in-iran-and-the-world 0.8 https://vaccinescongress.com/program/scientific-program/2022/new-technologies-in-shrimp-and-other-crustacean-vaccines 0.8 https://vaccinescongress.com/program/scientific-program/2022/characterization-of-attenuated-genotype-1-strain-of-japanese-encephalitis-virus 0.8 https://vaccinescongress.com/program/scientific-program/2022/introducing-the-latest-new-findings-regarding-covid-19-vaccine-in-iran-and-the-world 0.8 https://vaccinescongress.com/program/scientific-program/2022/introducing-the-recent-developments-in-the-production-of-various-covid-19-vaccines-in-iran 0.8 https://vaccinescongress.com/program/scientific-program/2022/an-update-on-childhood-immunisation-africa-perspective 0.8 https://vaccinescongress.com/program/scientific-program/2022/attitude-of-pregnant-and-lactating-women-toward-covid-19-vaccination-in-jordan-a-cross-sectional-study 0.8 https://vaccinescongress.com/program/scientific-program/2022/igg-and-igm-antibody-markers-for-immune-monitoring-in-therapeutic-cancer-vaccine 0.8 https://vaccinescongress.com/program/scientific-program/2022/lassa-fever-virus-vaccine-where-are-we 0.8 https://vaccinescongress.com/program/scientific-program/2022/studies-on-the-evolution-of-a-sars-cov-2-variant-of-concern-the-story-of-immune-escape-in-an-immunocompromised-patient 0.8 https://vaccinescongress.com/program/scientific-program/2022/the-involvement-of-the-nurses-in-vaccination-process-history-advantages-limitations-challenges-and-perspective-of-their-role-in-the-future 0.8 https://vaccinescongress.com/program/scientific-program/2021/characterising-the-dendritic-cell-response-to-bcg-using-a-bovine-afferent-lymphatic-cannulation-model-and-single-cell-rna-seq 0.8 https://vaccinescongress.com/program/scientific-program/2021/bovine-leukemia-virus-tax-gene-tax-protein-and-premirna-genes-polymorphism-and-its-relation-to-enzootic-bovine-leukosis 0.8 https://vaccinescongress.com/program/scientific-program/2021/identification-of-hobi-like-pestivirus-as-a-contaminant-of-the-vaccine-against-peste-des-petits-ruminants 0.8 https://vaccinescongress.com/program/scientific-program/2021/immunogenicity-of-dna-vaccines-based-on-multicistronic-vectors-and-synthetic-dna-delivery-systems 0.8 https://vaccinescongress.com/program/scientific-program/2021/fluorescence-a-teem-method-for-vaccines-characterization 0.8 https://vaccinescongress.com/program/scientific-program/2021/is-the-mandatory-implementation-of-a-passport-for-covid-19-vaccine-reduce-the-transmission-or-not 0.8 https://vaccinescongress.com/program/scientific-program/2021/vaccine-against-s-pyogenes 0.8 https://vaccinescongress.com/program/scientific-program/2021/covid-19-vaccines-contraindications 0.8 https://vaccinescongress.com/program/scientific-program/2021/ino-4500-a-dna-based-lasv-vaccine-induces-robust-t-cell-responses-and-long-term-memory-antigen-specific-t-cells 0.8 https://vaccinescongress.com/program/scientific-program/2021/nature-inspired-nanoparticle-based-dna-vaccine 0.8 https://vaccinescongress.com/program/scientific-program/2021/production-and-biological-characterization-of-egg-yolk-antibodies-igy-against-ftr1-iron-permease-of-candida-albicans 0.8 https://vaccinescongress.com/program/scientific-program/2021/development-of-universal-influenza-vaccine-using-m2e-conjugated-plga-nanoparticle 0.8 https://vaccinescongress.com/program/scientific-program/2021/focus-on-vaccine-safety-the-clinical-relevance-to-keep-focusing-on-the-close-monitoring-and-safety-surveillance-of-covid-19-available-and-forthcoming-vaccines-can-all-the-available-and-future-safety-clinical-data-be-conveyed-in-one-global-safety-database 0.8 https://vaccinescongress.com/program/scientific-program/2021/endosomal-tlrs-may-have-no-important-effect-on-higher-transmissibility-of-sars-cov-2-alpha-and-delta-variants 0.8 https://vaccinescongress.com/program/scientific-program/2021/aureolic-acid-group-of-agents-as-potential-antituberculosis-drugs 0.8 https://vaccinescongress.com/program/scientific-program/2021/vaccination-and-acute-flare-ups-in-rheumatoid-arthritis-a-nationwide-case-crossover-study-using-the-french-snds-health-care-databases 0.8 https://vaccinescongress.com/program/scientific-program/2021/partial-protection-of-sinopharm-vaccine-in-recent-sars-cov-2-outbreak-in-bahrain 0.8 https://vaccinescongress.com/program/scientific-program/2021/design-of-a-multi-epitope-vaccine-using-immunoinformatics-approach 0.8 https://vaccinescongress.com/program/scientific-program/2021/factors-influencing-public-attitudes-towards-covid-19-vaccination-a-scoping-review-informed-by-the-socio-ecological-model 0.8 https://vaccinescongress.com/program/scientific-program/2021/anti-sars-cov-2-antibodies-among-vaccinated-healthcare-workers-repeated-cross-sectional-study-in-vimsar-burla 0.8 https://vaccinescongress.com/program/scientific-program/2021/micro-encapsulations-of-outer-membrane-proteins-of-brucella-spp-highly-potent-vaccines-against-brucellosis 0.8 https://vaccinescongress.com/program/scientific-program/2021/introduce-of-most-important-aquatic-vaccines-in-aquaculture-and-marine-fish 0.8 https://vaccinescongress.com/program/scientific-program/2021/does-fever-increase-or-decrease-blood-circulation 0.8 https://vaccinescongress.com/program/scientific-program/2021/immunoinformatics-and-structural-analysis-for-multi-protein-vaccine-design 0.8 https://vaccinescongress.com/program/scientific-program/2021/phenotypic-and-genotypic-comparison-of-a-live-attenuated-genotype-i-japanese-encephalitis-virus-sd12-f120-strain-with-its-virulent-parental-sd12-strain-in-vitro-in-vivo 0.8 https://vaccinescongress.com/program/scientific-program/2021/comparison-of-several-developed-new-vaccines-against-covid-19 0.8 https://vaccinescongress.com/program/scientific-program/2021/fever-is-not-a-symptom-in-covid-19-none-of-the-diseases-require-fever-as-its-symptom 0.8 https://vaccinescongress.com/program/scientific-program/2021/covid-19-vaccine-its-present-situation-in-the-whole-world 0.8 https://vaccinescongress.com/program/scientific-program/2021/vaccine-hesitancy-and-influenza-vaccine-uptake-among-children-and-adults-a-cross-sectional-survey 0.8 https://vaccinescongress.com/program/scientific-sessions/advances-in-vaccine-research-and-development 0.9 https://vaccinescongress.com/program/scientific-sessions/mechanisms-of-vaccine-action-immune-response 0.9 https://vaccinescongress.com/program/scientific-sessions/novel-vaccine-delivery-systems 0.9 https://vaccinescongress.com/program/scientific-sessions/vaccine-adjuvants-and-immunomodulators 0.9 https://vaccinescongress.com/program/scientific-sessions/live-attenuated-inactivated-subunit-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/synthetic-and-peptide-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/conjugate-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/mrna-and-dna-based-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/toxoid-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/viral-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/bacterial-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/parasitic-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/cancer-vaccines-and-immunotherapy 0.9 https://vaccinescongress.com/program/scientific-sessions/covid-19-vaccines-lessons-future-applications 0.9 https://vaccinescongress.com/program/scientific-sessions/vaccines-for-emerging-and-re-emerging-infectious-diseases 0.9 https://vaccinescongress.com/program/scientific-sessions/neglected-tropical-disease-ntd-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/pediatric-vaccination-challenges-and-progress 0.9 https://vaccinescongress.com/program/scientific-sessions/vaccination-in-the-elderly 0.9 https://vaccinescongress.com/program/scientific-sessions/maternal-immunization-and-neonatal-protection 0.9 https://vaccinescongress.com/program/scientific-sessions/vaccines-for-immunocompromised-individuals 0.9 https://vaccinescongress.com/program/scientific-sessions/occupational-and-travel-related-vaccinations 0.9 https://vaccinescongress.com/program/scientific-sessions/bioprocessing-formulation-stability-of-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/disease-specific-vaccine-research 0.9 https://vaccinescongress.com/program/scientific-sessions/ai-and-machine-learning-in-vaccine-research 0.9 https://vaccinescongress.com/program/scientific-sessions/genomics-proteomics-and-systems-biology-in-vaccinology 0.9 https://vaccinescongress.com/program/scientific-sessions/global-vaccine-policies-and-regulation 0.9 https://vaccinescongress.com/program/scientific-sessions/ethical-legal-and-social-aspects-of-vaccination 0.9 https://vaccinescongress.com/program/scientific-sessions/vaccine-accessibility-and-equity-in-low-resource-settings 0.9 https://vaccinescongress.com/program/scientific-sessions/clinical-trials-design-monitoring-outcomes 0.9 https://vaccinescongress.com/program/scientific-sessions/vaccine-safety-surveillance-and-pharmacovigilance 0.9 https://vaccinescongress.com/program/scientific-sessions/bridging-preclinical-to-clinical-vaccine-development 0.9 https://vaccinescongress.com/program/scientific-sessions/regulatory-pathways-and-approval-processes 0.9 https://vaccinescongress.com/program/scientific-sessions/post-marketing-surveillance-and-real-world-data 0.9 https://vaccinescongress.com/program/scientific-sessions/one-health-and-zoonotic-vaccines 0.9 https://vaccinescongress.com/program/scientific-sessions/vaccines-and-antimicrobial-resistance 0.9 https://vaccinescongress.com/program/scientific-sessions/reverse-vaccinology-and-immunoinformatics 0.9 https://vaccinescongress.com/program/scientific-sessions/next-generation-vaccine-technologies 0.9 https://vaccinescongress.com/uploads/pdfs/conference-brochure.pdf 0.8 https://vaccinescongress.com/uploads/pdfs/final-program.pdf 0.8 https://vaccinescongress.com/uploads/pdfs/tentative-program.pdf 0.8 https://vaccinescongress.com/uploads/pdfs/abstract-book.pdf 0.8 https://vaccinescongress.com/uploads/pdfs/initial-announcement.pdf 0.8 https://vaccinescongress.com/uploads/pdfs/abstract-submission-sample.docx 0.8 https://vaccinescongress.com/uploads/pdfs/sponsors-exhibitors.pdf 0.8 https://vaccinescongress.com/2025 0.8 https://cloud.magnusgroup.online/ivc/book/pdf/ivc-2025.pdf 0.8 https://cloud.magnusgroup.online/ivc/program/pdf/ivc-2025.pdf 0.8 https://vaccinescongress.com/2024 0.8 https://cloud.magnusgroup.online/ivc/book/pdf/ivc-2024.pdf 0.8 https://cloud.magnusgroup.online/ivc/program/pdf/ivc-2024.pdf 0.8 https://vaccinescongress.com/2023 0.8 https://cloud.magnusgroup.online/ivc/book/pdf/ivc-2023.pdf 0.8 https://cloud.magnusgroup.online/ivc/program/pdf/ivc-2023.pdf 0.8 https://vaccinescongress.com/2022 0.8 https://cloud.magnusgroup.online/ivc/book/pdf/ivc-2022.pdf 0.8 https://cloud.magnusgroup.online/ivc/program/pdf/ivc-2022.pdf 0.8 https://vaccinescongress.com/2021 0.8 https://cloud.magnusgroup.online/ivc/book/pdf/ivc-2021.pdf 0.8 https://cloud.magnusgroup.online/ivc/program/pdf/ivc-2021.pdf 0.8